Active, not recruitingPhase 3NCT06037460
TocilizuMab discontinuAtion in GIant Cell Arteritis
Studying Giant cell arteritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centre Hospitalier Universitaire Dijon
- Intervention
- Tocilizumab treatment(drug)
- Enrollment
- 120 enrolled
- Eligibility
- 51 years · All sexes
- Timeline
- 2024 – 2028
Study locations (1)
- Chu Dijon Bourgogne, Dijon, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06037460 on ClinicalTrials.govOther trials for Giant cell arteritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07108387Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell ArteritisNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGNCT07084480Giant Cell Arteritis - Ways to Precision MedicineWuerzburg University Hospital
- RECRUITINGNANCT07001059oPtic Nerve Sheath Evaluation in gianT Cell aRtheritis by UltraSoundHôpital NOVO
- RECRUITINGNCT06894602Association of Ultrasonographic Temporal Artery Lesions and Relapse in Patients With Giant Cell ArteritisUniversity Hospital, Brest
- RECRUITINGNCT05749094Optic Nerve Sheath Ultrasound in Giant Cell ArteritisCentre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
- ACTIVE NOT RECRUITINGNCT05703763The Applanation Tonometry in GCA PilotCentre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
- RECRUITINGPHASE2NCT06887062Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)University of Edinburgh
- RECRUITINGNCT06742671Performance of a Fast-track Pathway for Giant Cell Arteritis DiagnosisGroupe Hospitalier de la Rochelle Ré Aunis